Evidence map›Paper›PMID 32652955›Full record

ArticleBMC nephrology2020

Ockham's razor defeated: about two atypical cases of hemolytic uremic syndrome.

Chloe Schwarz, Alice Brehon, Cyril Mousseaux, Yosu Luque, Patricia Senet, Patricia Mariani, Inna Mohamadou, Lara Zafrani, Véronique Frémeaux-Bacchi, Eric Rondeau and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Chloe SchwarzService d'urgences néphrologiques et transplantation rénale, hôpital Tenon, Paris, France. chloe.schwarz@gmail.com.ORCID 0000-0002-4742-7939
Alice BrehonService de dermatologie, hôpital Tenon, Paris, France.
Cyril MousseauxService d'urgences néphrologiques et transplantation rénale, hôpital Tenon, Paris, France.
Yosu LuqueService d'urgences néphrologiques et transplantation rénale, hôpital Tenon, Paris, France.
Patricia SenetService de dermatologie, hôpital Tenon, Paris, France.
Patricia MarianiService de microbiologie, hôpital Robert Debré, Paris, France.
Inna MohamadouService d'urgences néphrologiques et transplantation rénale, hôpital Tenon, Paris, France.
Lara ZafraniService de Médecine Intensive et Réanimation, hôpital Saint Louis, Paris, France.
Véronique Frémeaux-BacchiService d'immunologie, Hôpital Européen Georges Pompidou, Paris, France.
Eric RondeauService d'urgences néphrologiques et transplantation rénale, hôpital Tenon, Paris, France.
David BuobService d'anatomopathologie, hôpital Tenon, Paris, France.
Cédric RafatService d'urgences néphrologiques et transplantation rénale, hôpital Tenon, Paris, France.
Sorbonne Université · FRHôpital Européen Georges-Pompidou · FRHôpital Robert-Debré · FRHôpital Saint-Louis · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMedical investigation is a favorite application of Ockham's razor, in virtue of which when presented with competing hypotheses, the solution with the fewest assumptions should be privileged. Hemolytic uremic syndrome (HUS) encompasses diseases with distinct pathological mechanisms, such as HUS due to shiga-like toxin-producing bacteria (STEC-HUS) and atypical HUS, linked to defects in the alternate complement pathway. Other etiologies such as Parvovirus B19 infection are exceptional. All these causes are rare to such extent that we usually consider them mutually exclusive. We report here two cases of HUS that could be traced to multiple causes. CASES PRESENTATION: Case 1 presented as vomiting and diarrhea. All biological characteristics of HUS were present. STEC was found in stool (by PCR and culture). After initial remission, a recurrence occurred and patient was started on Eculizumab. Genetic analysis revealed the heterozygous presence of a CFHR1/CFH hybrid gene. The issue was favorable under treatment. In case 2, HUS presented as fever, vomiting and purpura of the lower limbs. Skin lesions and erythroblastopenia led to suspect Parvovirus B19 primo-infection, which was confirmed by peripheral blood and medullar PCR. Concurrently, stool culture and PCR revealed the presence of STEC. Evolution showed spontaneous recovery.

conclusionsBoth cases defy Ockham's razor in the sense that multiple causes could be traced to a single outcome; furthermore, they invite us to reflect on the physiopathology of HUS as they question the classical distinction between STEC-HUS and atypical HUS. We propose a two-hit mechanism model leading to HUS. Indeed, in case 1, HUS unfolded as a result of the synergistic interaction between an infectious trigger and a genetic predisposition. In case 2 however, it is the simultaneous occurrence of two infectious triggers that led to HUS. In dissent from Ockham's razor, an exceptional disease such as HUS may stem from the sequential occurrence or co-occurrence of several rare conditions.

Indexed as

AdultAntibodies, Monoclonal, HumanizedAtypical Hemolytic Uremic SyndromeComplement C3b Inactivator ProteinsComplement Factor HDiarrheaErythema InfectiosumEscherichia coli InfectionsGenetic TestingHemolytic-Uremic SyndromeHeterozygoteHumansMaleRecurrenceShiga-Toxigenic Escherichia coliVomitingAntibodies, Monoclonal, HumanizedCFH protein, humanCFHR1 protein, humanComplement C3b Inactivator ProteinsComplement Factor HeculizumabaHUSCase reportHUSParvovirus B19PhysiopathologySTEC

Identifiers

PMID32652955
PMCPMC7353709
OpenAlexW3041710942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.